Tharimmune (THAR) Competitors $1.40 +0.03 (+1.82%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. LEXX, BFRG, PMN, GOVX, PRPH, LPTX, VYNE, ALVR, FLGC, and MEIPShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Lexaria Bioscience (LEXX), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Leap Therapeutics (LPTX), VYNE Therapeutics (VYNE), AlloVir (ALVR), Flora Growth (FLGC), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Lexaria Bioscience Bullfrog AI ProMIS Neurosciences GeoVax Labs ProPhase Labs Leap Therapeutics VYNE Therapeutics AlloVir Flora Growth MEI Pharma Tharimmune (NASDAQ:THAR) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Is THAR or LEXX more profitable? Tharimmune has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,473.04%. Lexaria Bioscience's return on equity of -88.88% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% Lexaria Bioscience -1,473.04%-88.88%-83.59% Does the MarketBeat Community believe in THAR or LEXX? Lexaria Bioscience received 5 more outperform votes than Tharimmune when rated by MarketBeat users. CompanyUnderperformOutperformTharimmuneOutperform Votes2100.00% Underperform VotesNo VotesLexaria BioscienceOutperform Votes7100.00% Underperform VotesNo Votes Does the media refer more to THAR or LEXX? In the previous week, Lexaria Bioscience had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.47 indicating that Tharimmune is being referred to more favorably in the media. Company Overall Sentiment Tharimmune Very Positive Lexaria Bioscience Neutral Do institutionals & insiders have more ownership in THAR or LEXX? 1.2% of Tharimmune shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 10.0% of Tharimmune shares are held by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, THAR or LEXX? Lexaria Bioscience has higher revenue and earnings than Tharimmune. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32M-$7.88-0.18Lexaria Bioscience$525.92K32.32-$5.80M-$0.59-1.64 Do analysts rate THAR or LEXX? Tharimmune presently has a consensus target price of $17.00, suggesting a potential upside of 1,118.64%. Lexaria Bioscience has a consensus target price of $7.00, suggesting a potential upside of 623.14%. Given Tharimmune's stronger consensus rating and higher possible upside, research analysts clearly believe Tharimmune is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, THAR or LEXX? Tharimmune has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. SummaryLexaria Bioscience beats Tharimmune on 9 of the 16 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71M$6.92B$5.61B$8.62BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-0.188.6727.1419.96Price / SalesN/A262.53414.30157.63Price / CashN/A65.8538.2534.64Price / Book0.016.597.074.69Net Income-$9.32M$143.75M$3.23B$248.14M7 Day Performance-7.61%0.67%0.71%0.91%1 Month Performance-3.13%11.92%9.65%5.71%1 Year Performance-58.23%4.33%32.07%14.71% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.4316 of 5 stars$1.40+1.8%$17.00+1,118.6%-55.4%$3.71MN/A-0.182Positive NewsLEXXLexaria Bioscience2.5578 of 5 stars$0.92-5.7%$7.00+659.9%-68.5%$16.18M$525.92K-1.847News CoveragePositive NewsBFRGBullfrog AI1.6872 of 5 stars$1.71flatN/A-33.2%$16.10M$60K-2.014News CoveragePMNProMIS Neurosciences2.3648 of 5 stars$0.49-2.0%$4.50+818.4%-69.0%$16.02MN/A-4.905Gap UpGOVXGeoVax Labs3.4189 of 5 stars$1.05+1.0%$11.10+957.1%-23.1%$15.95M$5.59M-0.2910News CoveragePRPHProPhase Labs1.2835 of 5 stars$0.38+1.9%N/A-92.9%$15.82M$5.85M-0.30130Short Interest ↑LPTXLeap Therapeutics2.7422 of 5 stars$0.37+3.3%$4.92+1,227.0%-80.5%$15.35MN/A-0.1940Positive NewsVYNEVYNE Therapeutics2.5158 of 5 stars$1.00+7.8%$6.25+525.0%-58.6%$15.18M$605K-1.1630Short Interest ↑High Trading VolumeALVRAlloVirN/A$3.00+3.4%N/A-84.0%$15.13MN/A-0.15110News CoverageFLGCFlora Growth2.7547 of 5 stars$0.66+3.2%$4.00+505.6%-30.7%$14.91M$53.26M-0.67280Positive NewsMEIPMEI Pharma1.7116 of 5 stars$2.15-3.2%N/A-21.3%$14.32M$65.30M-0.38100News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies Lexaria Bioscience Competitors Bullfrog AI Competitors ProMIS Neurosciences Competitors GeoVax Labs Competitors ProPhase Labs Competitors Leap Therapeutics Competitors VYNE Therapeutics Competitors AlloVir Competitors Flora Growth Competitors MEI Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy THAR Stock Free THAR Stock Alerts